New drug for congenital Factor VII deficiency
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new drug called Sutacimig for people with congenital Factor VII deficiency, a rare bleeding disorder. The drug is designed to help prevent or control bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have confirmed Factor VII deficiency with an activity level below 10% (measured at least twice).
- You have a history of severe bleeding or have needed treatment with Factor VII or fresh frozen plasma for a bleed.
- You do not have inhibitors (antibodies) to Factor VII.
- You have not had a blood clot (such as a deep vein thrombosis or pulmonary embolism).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational injection called SR604 (given under the skin) to see if it can safely and effectively prevent and treat bleeding episodes in people with congenital factor VII deficiency, a rare condition that makes blood clotting hard. It is a phase 2 trial, meaning the drug is still being studied for its effects and safety.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This study tests a new medicine called denecimig (Mim8) for adults newly diagnosed with a rare bleeding disorder called acquired hemophilia A. If you have had a bleed that needs treatment, this trial could help you manage your condition.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
Hear when a new Congenital Factor VII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.